BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2021 10:23:34 AM | Browse: 491 | Download: 758
 |
Received |
|
2021-03-01 10:35 |
|
Peer-Review Started |
|
2021-03-01 10:35 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-15 03:00 |
|
Revised |
|
2021-07-25 09:51 |
|
Second Decision |
|
2021-08-06 03:17 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-08-06 07:49 |
|
Articles in Press |
|
2021-08-06 07:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-09-11 02:41 |
|
Publish the Manuscript Online |
|
2021-09-15 10:23 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Minireviews |
| Article Title |
Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Annalisa Maraone, Lorenzo Tarsitani, Irene Pinucci and Massimo Pasquini |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Massimo Pasquini, MD, PhD, Associate Professor, Department of Human Neurosciences, Sapienza University of Rome, Viale dell'Università 30, Rome 00185, Lazio, Italy. massimo.pasquini@uniroma1.it |
| Key Words |
Obsessive-compulsive disorder; Antiglutamatergic agents; Glutammate; Early intervention; Neurophysiopathology; Duration of untreated illness |
| Core Tip |
In pathophysiology of obsessive-compulsive disorder (OCD), dysfunction of the cortico-striatal-thalamo-cortical (CSTC) loop could provoke an imbalance between goal-directed system and habit learning system. Glutamate is the principal neurotransmitter implicated in the CSTC model of OCD. Glutammate dysregulation and neurotoxicity seem to be correlated, thus, an early intervention and a reduction of duration of untreated illness appear central in treatment of OCD, as well as the use of glutamate-modulating drugs that could help to interrupt damage from neurotoxicity. |
| Publish Date |
2021-09-15 10:23 |
| Citation |
Maraone A, Tarsitani L, Pinucci I, Pasquini M. Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects? World J Psychiatr 2021; 11(9): 568-580 |
| URL |
https://www.wjgnet.com/2220-3206/full/v11/i9/568.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v11.i9.568 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
